Lawmakers target biogenerics as biotech revenue soars

Researchers for Barr Pharmaceuticals are beavering away at developing copycat biotech drugs at a research facility in Croatia as the generics business gears up for what it sees as an inevitable move to create a regulatory pathway for follow-on biologics in the U.S. The biotech industry has fiercely resisted biogenerics, insisting that any copycats would have to be thoroughly--and expensively--studied in order to be safe. But as The Wall Street Journal notes, the steadily rising amount of money being spent on biotech drugs makes this a hot issue for lawmakers. Express Scripts says that a bill paving the way to generic biotech therapies would save the U.S. alone $71 billion over 10 years, the bulk of that tied to Amgen's Epogen, a therapy for anemia, and the similar Procrit. The federal government spent $2 billion on Procrit in 2005.

- read the trend report from The Wall Street Journal (sub. req.)

ALSO: Morgan Stanley's Dr. Steven Harr has played an influential role in advising against high biotech drug prices. Report

PLUS: Lake Forest, IL-based Hospira is lobbying for the biogeneric bill in Washington. Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.